Treating urinary incontinence using (S)-desethyloxybutynin
Patent 5677346 Issued on October 14, 1997. Estimated Expiration Date: June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/617, R contains benzene ring424/449, Transdermal or percutaneous424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/464, Tablets, lozenges, or pills514/310, Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding514/946PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED)
A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin, (S)-desethyloxybutynin or a pharmaceutically acceptable salt thereof, substantially free of the corresponding R enantiomer. Pharmaceutical compositions in the form of tablets and transdermal devices comprising (S)-oxybutynin or (S)-desethyloxybutynin and an acceptable carrier are also disclosed, as is a synthesis of desethyloxybutynin.
Other References
Lindeke et al. "Metabolism of Oxybutnin: Establishment of Desethyloxybutynin and Oxybutynin N-Oxide Formation in Rat Liver Preparations Using Deuterium Substitution and Gas Chromatographic Mass Spectrometric Analysis" Biomedical Mass Spectrometry, vol. 8, No. 10, 506-513 (1981)
Kasama et al. "Preparation of Substituted Glycolic acid 4-alkyl=amino-2-butynyl Esters as Antispasmodics and for Regulation of Urination" Chemical Abstracts, vol 113:23118k, 586 (1990)
Lish et al. "Oxybutynin--A Musculotropic Antispamodic Drug . . . " Arch. int. Pharmacodyn. 156, 456-488 (1965)
Hock "Clinical Evalution of Oxybutynin Chloride" Current Therpapeutic Research 9, 437-440 (1967)
Fredericks et al. "A Study of the Anticholinergic and Antispasmodic Activity of Oxybutynin . . . " Investigative Urology 12, 317-319 (1975)
Nilvebrant et al. "Dicyclomine, Benzhexol and Oxybutynine Distinguish . . . " Europ. J. Pharmacol. 123, 133-143 (1986)
Tonini et al. "Depressant action of oxybutynin on the contractility . . . " J. Pharm. Pharmacol. 39, 103-107 (1986)
Kachur et al. "R and S Enantiomers of Oxybutynin: Pharmacological Effects . . . " J. Pharm. Exper. Ther. 247, 867-872 (1988)
Noronha-Blob et al. "Muscarinic Receptors: Relationships Among Phosphoinositide . . . " J. Pharm. Exper. Ther. 249, 843-851 (1989)
Noronha-Blob et al. "The Anticholinergic Activity of Agents Indicated for Urinary . . . " J. Pharm. Exper. Ther. 251, 586-593 (1989)
Peterson et al. "In Vivo Cystometrogram Studies in Urethane-Anesthetized and Conscious Guinea Pigs" J. Pharm. Methods 21, 231-241 (1989)
Guarneri et al. "Effects of Oxybutynin, Terodiline, and Nifedipine . . . " Pharm. Research. 24, 263-272 (1991)
Noronha-Blob et al. "Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization . . . " J. Pharm. Exp. Ther . 256, 562-567 (1990)
Lowe et al. "Effect of extracellular Ca2+ on cholinergic, KCL and phorbol ester-mediated . . . " Eur. J. Pharm. 195, 237-279 (1991)
Massad et al. "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride" J. Urology 148, 595-597 (1992)
Angelico et al. "In Vivo Effects of Different Antispasmodic Drugs on the Rat Bladder Contractions" J. Pharm. Methods 27, 33-39 (1992)
Guarneri et al. "Effects of Drugs Used in the Therapy of Detrusor Hyperactivity. . . " Pharm. Research 27, 173-187 (1993)
Hughes et al. "Measurement of oxybutynin and its N-desethyl metabolite in plasma, and . . . " Xenobiotica 22, 859-869 (1992)
Take et al. "Agents for the Treatment of Overactive Detrusor, III. Synthesis and . . . " Chem. Pharm. Bull. 40, 1415-1423 (1992)